Researchers at the University of Pittsburgh say a new minimally invasive intervention can target the root cause of neural function loss.
The US Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback